MADCAM1 and neoplasm: This reduction in MAdCAM-1 decreases gut retention of immunosuppressive α4β7 + CD4 + regulatory T cells (Treg17), promoting their migration to tumor sites and consequently influencing PD-1 immunotherapy efficacy (Fidelle et al., 2023).